tetano
Editor, Senior Moderator
Pediatr Infect Dis J
. 2023 Mar 30.
doi: 10.1097/INF.0000000000003928. Online ahead of print.
The Infection Profile and Survival of Children and Adolescents With COVID-19 Undergoing Cancer Treatment: A Cohort Study
Ana Luiza Magalhães de Andrade-Lima[SUP] 1 [/SUP], Mecneide Mendes Lins[SUP] 2 [/SUP], Maria do Céu Diniz Borborema[SUP] 2 [/SUP], Ana Paula Rodrigues Matos[SUP] 2 [/SUP], Kaline Maria Maciel de Oliveira[SUP] 2 [/SUP], Maria Júlia Gonçalves Mello[SUP] 3 [/SUP]
Affiliations
Abstract
Objective: The objective of this study was to evaluate the clinical evolution of coronavirus disease 2019 (COVID-19) in children and adolescents with cancer.
Methods: Cohort involving patients undergoing cancer treatment, aged 19 years and under, with the diagnosis of COVID-19 by real-time polymerase chain reaction, in a reference hospital, between March 2020 and November 2021. Data were collected from medical records and interviews with patients and/or guardians. The primary outcomes studied were severe/critical COVID-19 presentation, deaths from any cause and overall survival. The Cox proportional hazards multivariate regression analysis was performed to determine the risk of death.
Results: Sixty-two participants were included, most (67.7%) were male, with a median age of 6.8 years. Severe/critical forms of COVID-19, observed in 24.2%, seemed to indicate that the pediatric population undergoing cancer treatment has a higher morbidity rate than the general pediatric population (8-9.2%). During follow-up (4.5-18 months), 20 patients (32.3%) completed their cancer treatment and 18 died (29%)-6 during hospitalization and 12 after discharge. In total 61.1% of deaths occurred within 63 days of a detectable real-time polymerase chain reaction. Patients with a higher risk of death presented with severe/critical COVID-19 [adjusted hazard risk (aHR): 8.51; 95% confidence interval (CI): 2.91-24.80; P < 0.00] solid tumors (aHR: 3.99; 95% CI: 1.43-11.12; P = 0.008) and diarrhea as a symptom of COVID-19 (aHR: 3.9; 95% CI: 1.23-12.73; P = 0.021).
Conclusions: These findings support the impact that severe acute respiratory syndrome-associated coronavirus 2 infection has on the population of children and adolescents with cancer, not only regarding immediate severity but also in their survival rate. Further studies evaluating long-term outcomes of COVID-19 in children and adolescents with cancer should be encouraged.
. 2023 Mar 30.
doi: 10.1097/INF.0000000000003928. Online ahead of print.
The Infection Profile and Survival of Children and Adolescents With COVID-19 Undergoing Cancer Treatment: A Cohort Study
Ana Luiza Magalhães de Andrade-Lima[SUP] 1 [/SUP], Mecneide Mendes Lins[SUP] 2 [/SUP], Maria do Céu Diniz Borborema[SUP] 2 [/SUP], Ana Paula Rodrigues Matos[SUP] 2 [/SUP], Kaline Maria Maciel de Oliveira[SUP] 2 [/SUP], Maria Júlia Gonçalves Mello[SUP] 3 [/SUP]
Affiliations
- PMID: 37053592
- DOI: 10.1097/INF.0000000000003928
Abstract
Objective: The objective of this study was to evaluate the clinical evolution of coronavirus disease 2019 (COVID-19) in children and adolescents with cancer.
Methods: Cohort involving patients undergoing cancer treatment, aged 19 years and under, with the diagnosis of COVID-19 by real-time polymerase chain reaction, in a reference hospital, between March 2020 and November 2021. Data were collected from medical records and interviews with patients and/or guardians. The primary outcomes studied were severe/critical COVID-19 presentation, deaths from any cause and overall survival. The Cox proportional hazards multivariate regression analysis was performed to determine the risk of death.
Results: Sixty-two participants were included, most (67.7%) were male, with a median age of 6.8 years. Severe/critical forms of COVID-19, observed in 24.2%, seemed to indicate that the pediatric population undergoing cancer treatment has a higher morbidity rate than the general pediatric population (8-9.2%). During follow-up (4.5-18 months), 20 patients (32.3%) completed their cancer treatment and 18 died (29%)-6 during hospitalization and 12 after discharge. In total 61.1% of deaths occurred within 63 days of a detectable real-time polymerase chain reaction. Patients with a higher risk of death presented with severe/critical COVID-19 [adjusted hazard risk (aHR): 8.51; 95% confidence interval (CI): 2.91-24.80; P < 0.00] solid tumors (aHR: 3.99; 95% CI: 1.43-11.12; P = 0.008) and diarrhea as a symptom of COVID-19 (aHR: 3.9; 95% CI: 1.23-12.73; P = 0.021).
Conclusions: These findings support the impact that severe acute respiratory syndrome-associated coronavirus 2 infection has on the population of children and adolescents with cancer, not only regarding immediate severity but also in their survival rate. Further studies evaluating long-term outcomes of COVID-19 in children and adolescents with cancer should be encouraged.